Skip to main content
Top
Published in: Aesthetic Plastic Surgery 2/2007

01-04-2007

Reconstituted Botulinum Type A Neurotoxin: Clinical Efficacy After Long-Term Freezing Before Use

Authors: Alan A. Parsa, M.D., Kevin D. Lye, M.D., Fereydoun Don Parsa, M.D., F.A.C.S.

Published in: Aesthetic Plastic Surgery | Issue 2/2007

Login to get access

Abstract

Botulinum neurotoxin type A (BoNT/A) is injected into muscles of facial expression for treatment of facial wrinkles. Manufacturers’ recommendations state that the product should be used within 4 h of reconstitution to prevent loss of effectiveness. A prospective study was undertaken to evaluate the effectiveness of reconstituted BoNT/A when preserved in a frozen state for up to 6 months, as compared with nonfrozen BoNT/A used within 4 h after reconstitution. Treatment of 118 sites in 80 patients was performed and evaluated for aesthetic efficacy. Excellent results were observed in 94.8% of sites treated with nonfrozen BoNT/A and in 93.3% of the sites treated with frozen and thawed BoNT/A (p = 1). Minor side effects were rare and transient in both groups. In contrast to common belief, reconstituted BoNT/A may be frozen, thawed, and injected without losing its potency for up to 6 months, with efficacy equivalent to that of freshly prepared BoNT/A.
Literature
1.
go back to reference Allergan, Inc: Botox cosmetic (botulinum toxin type A) purified neurotoxin complex [package insert]. Allergan, Inc., Irvine, CA, USA Allergan, Inc: Botox cosmetic (botulinum toxin type A) purified neurotoxin complex [package insert]. Allergan, Inc., Irvine, CA, USA
2.
go back to reference Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L: Treatment of blepharospasm with medication, surgery, and type A botulinum toxin. Can J Ophthalmol 22:24–28, 1987PubMed Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L: Treatment of blepharospasm with medication, surgery, and type A botulinum toxin. Can J Ophthalmol 22:24–28, 1987PubMed
3.
go back to reference Fagien S: Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: Adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 112:40s–52s, 2003CrossRef Fagien S: Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: Adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 112:40s–52s, 2003CrossRef
4.
go back to reference Freeman A (principal investigator): A randomized, multicenter, double-blind, placebo-controlled study of intramuscular BOTOX (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia. Data on file. Allergan, Inc., Irvine, CA, USA, June 1995–June 1998 Freeman A (principal investigator): A randomized, multicenter, double-blind, placebo-controlled study of intramuscular BOTOX (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia. Data on file. Allergan, Inc., Irvine, CA, USA, June 1995–June 1998
5.
go back to reference Guerrissi JO: Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow’s feet. Plast Reconstr Surg 112:161s–163s, 2003PubMedCrossRef Guerrissi JO: Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow’s feet. Plast Reconstr Surg 112:161s–163s, 2003PubMedCrossRef
6.
go back to reference Kim EJ, Ramirez AL, Reeck JB, Maas CS: The role of botulinum type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconst Surg 112:88s–93s, 2003zPubMedCrossRef Kim EJ, Ramirez AL, Reeck JB, Maas CS: The role of botulinum type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconst Surg 112:88s–93s, 2003zPubMedCrossRef
7.
go back to reference Koriazova LK, Montal M: Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10:13–18, 2003PubMedCrossRef Koriazova LK, Montal M: Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10:13–18, 2003PubMedCrossRef
8.
go back to reference Niamtu J: Cosmetic oral and maxillofacial surgery options. J Am Dent Assoc 131:756–764, 2000PubMed Niamtu J: Cosmetic oral and maxillofacial surgery options. J Am Dent Assoc 131:756–764, 2000PubMed
9.
go back to reference Parsa FD: How to avoid eyelid ptosis when injecting botulinum toxin into the corrugators. Plast Reconstr Surg 105:1564–1565, 2000PubMedCrossRef Parsa FD: How to avoid eyelid ptosis when injecting botulinum toxin into the corrugators. Plast Reconstr Surg 105:1564–1565, 2000PubMedCrossRef
11.
go back to reference Rohrich RJ, Janis JE, Fagien S, Stuzin JM: The cosmetic use of botulinum toxin. Plast Reconstr Surg 112:177s–187s, 2003PubMedCrossRef Rohrich RJ, Janis JE, Fagien S, Stuzin JM: The cosmetic use of botulinum toxin. Plast Reconstr Surg 112:177s–187s, 2003PubMedCrossRef
12.
go back to reference Singh BR: Critical aspects of bacterial protein toxins. Adv Exp Med Biol 391:63–84, 1996PubMed Singh BR: Critical aspects of bacterial protein toxins. Adv Exp Med Biol 391:63–84, 1996PubMed
13.
go back to reference Zhou Y, Singh BR: Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 34:8–16, 2004PubMedCrossRef Zhou Y, Singh BR: Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 34:8–16, 2004PubMedCrossRef
Metadata
Title
Reconstituted Botulinum Type A Neurotoxin: Clinical Efficacy After Long-Term Freezing Before Use
Authors
Alan A. Parsa, M.D.
Kevin D. Lye, M.D.
Fereydoun Don Parsa, M.D., F.A.C.S.
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Aesthetic Plastic Surgery / Issue 2/2007
Print ISSN: 0364-216X
Electronic ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-006-0161-1

Other articles of this Issue 2/2007

Aesthetic Plastic Surgery 2/2007 Go to the issue